CytomX Therapeutics (NASDAQ:CTMX) is set to release its earnings data after the market closes on Wednesday, August 7th. Analysts expect CytomX Therapeutics to post earnings of ($0.55) per share for the quarter.
CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.22. CytomX Therapeutics had a negative net margin of 111.27% and a negative return on equity of 73.62%. The company had revenue of $29.49 million during the quarter, compared to the consensus estimate of $13.59 million. On average, analysts expect CytomX Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
CTMX stock traded up $0.24 during trading on Wednesday, reaching $10.77. The company had a trading volume of 1,328 shares, compared to its average volume of 302,766. CytomX Therapeutics has a 52 week low of $8.94 and a 52 week high of $27.04. The stock has a market cap of $461.27 million, a P/E ratio of -5.17 and a beta of 0.64. The business’s 50 day moving average price is $11.00. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.21 and a current ratio of 4.21.
About CytomX Therapeutics
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Read More: What is a growth and income fund?
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.